Novartis disclosed nine reports; STAT says seven had not previously been public.
Why it matters: Zolgensma is a one-time gene therapy for spinal muscular atrophy in young children. The reports could affect regulatory monitoring and future label discussions, but causation has not been established.
- Novartis said it had received nine worldwide tumor reports since Zolgensma was first approved in 2019.
- STAT reported on Nov. 5, 2026, that seven of the nine reports had not previously been publicly disclosed.
- Two of three reports that underwent pathology testing showed evidence of Zolgensma vector DNA integration; six had incomplete pathology.
- The U.K. National Multidisciplinary Team said it was not recommending additional scans, testing or changes to routine care.
In a Novartis statement available by Nov. 4, 2026, the company said it had received nine worldwide reports of tumors in patients treated with Zolgensma since the therapy was first approved in 2019. The statement was reproduced by SMA UK.
On Nov. 5, 2026, STAT reported that seven of the nine reports had not previously been publicly disclosed. The reports should not be described as seven confirmed Zolgensma-caused cancers: A causal connection has not been established.
Pathology testing was completed in three reports. Two showed evidence of DNA from the therapy's AAV9 vector integrating into patients' DNA. Integration is the theoretical mechanism behind the therapy's tumorigenicity warning, but it does not prove that Zolgensma caused the tumors. One report appeared unrelated to treatment. Novartis said the two patients with evidence of vector integration received treatment for their tumors and remain under monitoring.
Zolgensma is an intravenous AAV9-based gene therapy designed to deliver a functional copy of the gene encoding survival motor neuron protein. Its U.S. label warns of a theoretical tumorigenicity risk from vector DNA integration and instructs providers to report tumors, according to the prescribing information.
Novartis said it notified health authorities and was working with regulators on next steps. SMA Europe said authorities were assessing the evidence. The U.K. National Multidisciplinary Team said that, based on information available as of Nov. 4, it was not recommending changes to routine follow-up or additional scans and tests.
The available materials do not identify the tumor types, countries, ages at diagnosis, treatment-to-detection timelines or outcomes for all nine reports.
By the numbers
- 9 - worldwide tumor reports Novartis said it had received since Zolgensma's 2019 approval
- 7 - reports STAT said had not previously been publicly disclosed
- 2 of 3 - pathology-tested reports showing evidence of vector DNA integration
Yes, but: Vector DNA integration does not establish that Zolgensma caused the tumors. Six reports had incomplete pathology, and the available materials do not provide full clinical details for all nine cases.
What's next: Novartis said it notified health authorities and was working with regulators on next steps. The U.K. National Multidisciplinary Team was not recommending additional scans, testing or changes to routine care as of Nov. 4, 2026.